ArticleFrontiers in oncology2022

Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma.

Ye Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.